Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...

ICON Public Limited (NASDAQ:ICLR – Get Free Report)’s share price reached a new 52-week low on Thursday after Truist Financial lowered their price target on the stock from $284.00 to $262.00. Truist ...

ICON Public (NASDAQ:ICLR – Get Free Report) had its price target reduced by equities researchers at JPMorgan Chase & Co. from $280.00 to $265.00 in a research note issued on Monday,Benzinga reports.

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools that ...

ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...

In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ ... The reason is simple: our research has shown that we can outperform the market by imitating the ...

ICON Public Limited Company (NASDAQ:ICLR) provides outsourced clinical research and commercialization services, supporting all stages of clinical development for pharmaceutical, biotechnology ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 ...